News | January 12, 2015

Trial to Evaluate Cryoballoon Ablation as First-Line Treatment for Patients with Symptomatic Paroxysmal Atrial Fibrillation

With prevalence of AF expected to increase exponentially over the next generation, cryoballoon ablation therapy may safely and effectively address the disease before it progresses

Ablation Systems, Atrial Fibrillation, EP Lab, Clinical Trial/Study

Image courtesy of Medtronic

January 12, 2015 — Medtronic Inc. announced the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Arctic Front Advance cryoballoon as a first-line treatment for atrial fibrillation (AF) patients. While medication is currently considered first-line treatment for AF, clinical research indicates that half of all patients with symptomatic disease do not respond to drug therapy; earlier ablation may improve treatment effectiveness.

The Cryo-FIRST (Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation) trial will evaluate the procedural success and clinical outcomes of patients with paroxysmal AF (PAF) undergoing cryoballoon ablation as an initial treatment compared with medication. It will include approximately 218 patients in up to 12 centers across Europe. Enrollments have occurred at Heart Rhythm Management Centre, UZ Brussel-VUB Brussel (Brussels, Belgium); Clinique Saint Gatien (Tours, France); CHU d' Amiens (Amien, France) and Kerckhoff-Klinik (Bad Nauheim, Germany).

The most recent European guidelines highlight that ablation should be considered as first-line therapy in selected patients with symptomatic PAF. Cryoballoon ablation is not approved as a first-line treatment in the United States.

Cryoablation involves a minimally invasive procedure that creates lesions by freezing tissue in the heart's upper chambers, traditionally around the pulmonary veins, to block the electrical signals that trigger erratic heart rhythms. Pulmonary vein isolation (PVI) is a standard treatment for patients in the early stages of AF when the triggers come largely from these veins. However, as the disease progresses, it becomes more complicated to treat, with lower long-term success rates.

For more information: www.medtronic.com 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init